Last reviewed · How we verify
Corticosteroid or pentoxifylline
Corticosteroid or pentoxifylline is a Corticosteroid + phosphodiesterase inhibitor combination Small molecule drug developed by Saint Vincent's Hospital, Korea. It is currently in Phase 3 development for Inflammatory or immune-mediated conditions under investigation in phase 3 trials.
This combination therapy uses corticosteroids to suppress inflammatory immune responses and pentoxifylline to improve blood flow and reduce inflammatory cytokine production.
This combination therapy uses corticosteroids to suppress inflammatory immune responses and pentoxifylline to improve blood flow and reduce inflammatory cytokine production. Used for Inflammatory or immune-mediated conditions under investigation in phase 3 trials.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Immunology slight uplift
+1.0pp
Mature endpoint landscape (ACR, DAS28, PASI) makes immunology approvals slightly more predictable.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Corticosteroid or pentoxifylline |
|---|---|
| Sponsor | Saint Vincent's Hospital, Korea |
| Drug class | Corticosteroid + phosphodiesterase inhibitor combination |
| Target | Glucocorticoid receptor; phosphodiesterase (non-selective) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Inflammatory disease |
| Phase | Phase 3 |
Mechanism of action
Corticosteroids work by binding glucocorticoid receptors to inhibit pro-inflammatory gene transcription and immune cell activation. Pentoxifylline is a phosphodiesterase inhibitor that reduces TNF-α and other inflammatory mediators while improving microcirculatory blood flow. Together, they provide complementary anti-inflammatory and rheological benefits.
Approved indications
- Inflammatory or immune-mediated conditions under investigation in phase 3 trials
Common side effects
- Infection (corticosteroid-related immunosuppression)
- Gastrointestinal upset (pentoxifylline)
- Hyperglycemia (corticosteroid-related)
- Insomnia or mood changes (corticosteroid-related)
Key clinical trials
- LLLT of Trophic Ulcers of Lower Extremities and Chronic Venous Insufficiency (NA)
- Rifaximin Use in Severe Alcoholic Hepatitis (PHASE3)
- Safety & Efficacy of the Extracorporeal Liver Assist Device (ELAD) System in Patients With Hepatic Insufficiency (PHASE1, PHASE2)
- Efficacy of Pentoxifylline on Primary Nephrotic Syndrome (PHASE3)
- Efficacy of Pentoxifylline on Rapidly Progressive Glomerulonephritis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Corticosteroid or pentoxifylline CI brief — competitive landscape report
- Corticosteroid or pentoxifylline updates RSS · CI watch RSS
- Saint Vincent's Hospital, Korea portfolio CI
Frequently asked questions about Corticosteroid or pentoxifylline
What is Corticosteroid or pentoxifylline?
How does Corticosteroid or pentoxifylline work?
What is Corticosteroid or pentoxifylline used for?
Who makes Corticosteroid or pentoxifylline?
What drug class is Corticosteroid or pentoxifylline in?
What development phase is Corticosteroid or pentoxifylline in?
What are the side effects of Corticosteroid or pentoxifylline?
What does Corticosteroid or pentoxifylline target?
Related
- Drug class: All Corticosteroid + phosphodiesterase inhibitor combination drugs
- Target: All drugs targeting Glucocorticoid receptor; phosphodiesterase (non-selective)
- Manufacturer: Saint Vincent's Hospital, Korea — full pipeline
- Therapeutic area: All drugs in Immunology / Inflammatory disease
- Indication: Drugs for Inflammatory or immune-mediated conditions under investigation in phase 3 trials
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing